Development of ICT01, a first-in-class, anti-BTN3A antibody for activating Vγ9Vδ2 T cell–mediated antitumor immune response
2021 · Science Translational Medicine · 102 citations
https://doi.org/10.1126/scitranslmed.abj0835
R
Rémy Castellano
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
434
Papers
4.6K
Citations
33
h-index
46
i10-index
Rémy Castellano is an academic researcher. The author has contributed to research in topics: Cancer, Lipids, and Metabolism & Ferroptosis and cancer prognosis & RNA modifications and cancer. The author has an h-index of 33, co-authored 369 publications.
ORCID: 0000-0002-0152-985XPapers by this author
worksA robust and rapid xenograft model to assess efficacy of chemotherapeutic agents for human acute myeloid leukemia
2015 · Blood Cancer Journal · 84 citations
https://doi.org/10.1038/bcj.2015.19
RAS activation induces synthetic lethality of MEK inhibition with mitochondrial oxidative metabolism in acute myeloid leukemia
2022 · Leukemia · 24 citations
https://doi.org/10.1038/s41375-022-01541-0
A chemogenomic approach to identify personalized therapy for patients with relapse or refractory acute myeloid leukemia: results of a prospective feasibility study
2020 · Blood Cancer Journal · 21 citations
https://doi.org/10.1038/s41408-020-0330-5
From a drug repositioning to a structure-based drug design approach to tackle acute lymphoblastic leukemia
2023 · Nature Communications · 13 citations
https://doi.org/10.1038/s41467-023-38668-2
Inhibition of the STAT3/Fanconi anemia axis is synthetic lethal with PARP inhibition in breast cancer
2025 · Nature Communications · 7 citations
https://doi.org/10.1038/s41467-025-57476-4
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat